Pomegra
Cochlear COH cut its final dividend by 40% to A$1.30 as FY26 underlying profit fell 22%, with shares and CSL pushing the ASX 200 0.2% higher to 9,062.60.
- Cochlear's underlying FY26 net profit declined 22% to A$322M; statutory profit fell 62% to A$147.3M.
- The final dividend was cut 40% to A$1.30 per share; the full-year payout dropped 20% to A$3.45.
- COH shares rose 7% on August 18, 2026, as results landed at the top of already-reset guidance.
Lead
Cochlear Limited (COH), the Sydney-based hearing implant maker, reported a 22% fall in underlying net profit to A$322 million for FY2026, prompting a 40% reduction in the final dividend to A$1.30 per share. Statutory net profit collapsed 62% to A$147.3 million after one-off charges. Despite the headline deterioration, COH shares surged 7% on August 18, 2026, after results landed at the upper end of heavily revised guidance, helping lift the market index ASX 200 by 0.2% to 9,062.60 alongside a strong session for CSL Limited (CSL).What Drove Cochlear's Profit Decline?
Cost-of-living pressures in the United States squeezed the services segment, where consumers delayed elective upgrades and accessories purchases. Manufacturing inefficiencies and an unfavorable product mix compressed margins further. Sales revenue rose 2% in constant currency to A$2.34 billion, but that top-line gain failed to offset the cost headwinds. Research and development expenditure climbed 15% as Cochlear accelerated its push into next-generation technology, including the Nucleus Nexa System - the company's first smart cochlear implant with upgradeable firmware - which captured more than 95% of implant sales in developed markets within months of launch.
Why Did the Dividend Fall So Steeply?
The full-year dividend of A$3.45 per share compares with A$4.31 in the prior year, a 20% reduction that tracked the underlying profit decline. Management framed the cut as a direct function of lower earnings, with the payout ratio maintained within the company's stated policy range rather than reflecting any structural shift in capital allocation. Elevated investment spending - covering R&D, the Nucleus Nexa rollout, and manufacturing infrastructure - is expected to persist into FY2027, limiting the scope for a near-term restoration of the prior payout level.
Why Did ASX Investors Bid Cochlear Higher Despite the Numbers?
Expectations had been thoroughly recalibrated. In February 2026, COH shares dropped 39% in a single session after management issued a sharp profit warning for the full year. With that guidance already embedded in the market, an FY26 result landing at the upper end of revised forecasts was read as confirmation that the bottom had been reached. The broader healthcare sector on the Sydney exchange advanced 8.1% on the day, with Pro Medicus (PME) and CSL contributing alongside Cochlear to one of the strongest sector sessions of the earnings season.
What Is Cochlear's FY27 Guidance?
For FY2027, Cochlear guided underlying net profit of A$330 million to A$350 million, a modest step up from A$322 million in FY26 but materially below the A$435-460 million range that had been targeted before the downgrade cycle began. Low single-digit revenue growth in constant currency is forecast. Management identified a gradual recovery in United States services revenue as the primary earnings lever, supported by continued Nucleus Nexa adoption as the company defends its dominant market position in cochlear implants across developed economies.
Outlook
Cochlear's earnings trajectory points to a slow rebuild from cycle lows, with FY27 guidance representing only incremental improvement above a reset base. The structural case for the hearing implant franchise remains intact - an aging global population, rising diagnosis rates, and expanding access in lower-income markets - but near-term performance depends on a durable rebound in discretionary healthcare spending in the United States and a return to operational efficiency at the manufacturing level. CSL and Cochlear's combined contribution on August 18 nudged the ASX 200 to 9,062.60, a 0.2% gain that reflected a broadly constructive earnings season for Australian healthcare rather than any change in the macro backdrop.
